Holen Sie sich die Stockscreener-App
9.7089
0.71%
0.0789
Schlusskurs vom Vortag:
$9.63
Offen:
$9.67
24-Stunden-Volumen:
151.56K
Relative Volume:
0.33
Marktkapitalisierung:
$337.04M
Einnahmen:
$85.23M
Nettoeinkommen (Verlust:
$2.70M
KGV:
154.60
EPS:
0.0628
Netto-Cashflow:
$20.97M
1W Leistung:
+9.10%
1M Leistung:
+6.81%
6M Leistung:
-10.20%
1J Leistung:
-11.91%
1-Tages-Spanne:
$9.47
$9.88
1-Wochen-Bereich:
$8.97
$9.88
52-Wochen-Spanne:
$8.12
$18.23
Delcath Systems Inc Stock (DCTH) Company Profile
Firmenname
Delcath Systems Inc
Sektor
Branche
Telefon
(518) 743-8892
Adresse
566 QUEENSBURY AVENUE, QUEENSBURY, NY
Compare DCTH vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DCTH
Delcath Systems Inc
|
9.70 | 334.61M | 85.23M | 2.70M | 20.97M | 0.0628 |
ABT
Abbott Laboratories
|
102.15 | 178.75B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
332.01 | 126.97B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.25 | 111.22B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.58 | 93.36B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
81.05 | 46.73B | 6.07B | 1.06B | 1.34B | 1.8063 |
Delcath Systems Inc Stock (DCTH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-28 | Eingeleitet | Craig Hallum | Buy |
| 2024-05-14 | Eingeleitet | Stephens | Overweight |
| 2022-07-26 | Fortgesetzt | Canaccord Genuity | Buy |
| 2021-12-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-09 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-01-05 | Eingeleitet | BTIG Research | Buy |
| 2020-06-01 | Eingeleitet | Laidlaw | Buy |
Alle ansehen
Delcath Systems Inc Aktie (DCTH) Neueste Nachrichten
Delcath Systems (DCTH) Gains Recognition in Clinical Guidelines - gurufocus.com
Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma - BioSpace
Delcath therapy included in European uveal melanoma guidelines By Investing.com - Investing.com India
Aug Levels: Is Delcath Systems Inc a strong candidate for buy and holdShort Setup & Risk Managed Investment Entry Signals - baoquankhu1.vn
EBIT per share of Delcath Systems, Inc. – MUN:DV3R - TradingView
DCTH PE Ratio & Valuation, Is DCTH Overvalued - Intellectia AI
Stock List: Research Stocks from Around the World - gurufocus.com
DV3R.SG,0P0000X679,0 (DV3R.SG) Stock Price, News, Quote & History - Yahoo! Finance Canada
Delcath Systems, Inc. (NASDAQ:DCTH) Q4 2025 earnings call transcript - MSN
Responsive Playbooks and the DCTH Inflection - Stock Traders Daily
Delcath Systems Inc. (US24661P8077.SG) Balance Sheet - Yahoo! Finance Canada
Delcath (NASDAQ: DCTH) seeks approval to expand 2020 equity incentive plan - Stock Titan
Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting - BioSpace
Delcath Systems (DCTH) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Decliners Report: What are the future prospects of Delcath Systems IncProduct Launch & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Are options traders betting on a big move in Delcath Systems stock? - MSN
Uveal Neoplasms Markets, Companies, and Investment Opportunities Analysis 2026-2030 - GlobeNewswire
Delcath Systems, Inc. (NASDAQ:DCTH) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Q3 2025 Delcath Systems Inc Earnings Call Transcript - GuruFocus
Risk Analysis: Is Delcath Systems Inc backed by strong institutional buyingForecast Cut & Daily Stock Trend Watchlist - baoquankhu1.vn
Market Catalysts: What is BDSXs 5 year growth outlookTrade Analysis Report & Safe Entry Zone Tips - baoquankhu1.vn
Understanding the Setup: (DCTH) and Scalable Risk - Stock Traders Daily
FRA:DV3R PB Ratio: 2.85 — 49% Below Median - GuruFocus
Form 13G DELCATH SYSTEMS For: 20 March By Investing.com - Investing.com Australia
Daniel Kaufman reports 5.08% stake in Delcath Systems (DCTH) - Stock Titan
Divisadero Street Capital Management LP Invests $5.12 Million in Delcath Systems, Inc. $DCTH - MarketBeat
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $250,000 from Inve - Yahoo
The Technical Signals Behind (DCTH) That Institutions Follow - Stock Traders Daily
Delcath Systems Charts Profitable Path Amid Heavy Investment - The Globe and Mail
Delcath Systems Q3 2025 Earnings Preview - MSN
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Delcath Systems (DCTH) - The Globe and Mail
Delcath Systems, Inc. (DCTH) Surpasses Q2 Earnings and Revenue Estimates - MSN
Can Delcath Systems Inc expand into new marketsQuarterly Earnings Report & Risk Managed Trade Strategies - baoquankhu1.vn
Insider Buying: Sandra Pennell Acquires Shares of Delcath Systems Inc (DCTH) - GuruFocus
Delcath Systems (DCTH) CFO purchases 5,533 common shares at $9.04 - Stock Titan
Fundamentals Check: Is Delcath Systems Inc a strong candidate for buy and holdMarket Performance Report & Accurate Intraday Trading Signals - baoquankhu1.vn
Propel Bio Management LLC Buys 212,457 Shares of Delcath Systems, Inc. $DCTH - MarketBeat
Delcath Systems publishes results from CHOPIN trial in The Lancet Oncology - Yahoo Finance
HC Wainwright Lowers Earnings Estimates for Delcath Systems - MarketBeat
Delcath announces publication of liver cancer treatment trial - Investing.com
Delcath announces publication of liver cancer treatment trial By Investing.com - Investing.com Canada
Delcath Highlights CHOPIN Phase 2 Results in Uveal Melanoma - TipRanks
Insider Buying: Gerard Michel Acquires Additional Shares of Delc - GuruFocus
CHOPIN uveal melanoma trial data in Lancet boosts Delcath (Nasdaq: DCTH) - Stock Titan
[Form 4] DELCATH SYSTEMS, INC. Insider Trading Activity - Stock Titan
Delcath Systems announces publication of Chopin clinical trial results in The Lancet Oncology - marketscreener.com
Delcath Systems, Inc. (NASDAQ:DCTH) Q4 2025 Earnings Call Transcript - Insider Monkey
Delcath Systems Announces Publication Of Chopin Clinical Trial Results In The Lancet Oncology - TradingView
Liver-directed therapy plus immunotherapy extends survival in uveal melanoma - Stock Titan
FY2029 EPS Forecast for Delcath Systems Decreased by Analyst - MarketBeat
Delcath Systems Reports Record 2025 Results, Outlines 2026 Growth Plan - National Today
Finanzdaten der Delcath Systems Inc-Aktie (DCTH)
Umsatz
Nettogewinn
Free Cashflow
ENV
Delcath Systems Inc-Aktie (DCTH) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sylvester John Richard | Director |
Nov 21 '25 |
Buy |
8.89 |
4,386 |
38,992 |
14,936 |
| MICHEL GERARD J | CHIEF EXECUTIVE OFFICER |
Nov 11 '25 |
Buy |
8.53 |
11,500 |
98,049 |
330,834 |
| Vukovic Vojo | CHIEF MEDICAL OFFICER |
Jun 12 '25 |
Option Exercise |
4.78 |
42,000 |
200,760 |
168,882 |
0.25%
0.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):